Sector: Healthcare|Industry: Medical Distribution|Market Cap: $8.95B|Employees: 25K
Henry Schein, Inc. provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution segment offers dental products, including infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, dental implants, gypsum, acrylics, articulators, abrasives, dental chairs, delivery units and lights, X-ray supplies and equipment, personal protective equipment, and high-tech and digital restoration equipment, as well as equipment repair services. This segment also provides medical products, such as branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, X-ray products, equipment, and vitamins. The Technology and Value-Added Services segment offers software, technology, and other value-added services that include practice management software systems for dental and medical practitioners; and value-added practice solutions comprising practice consultancy, education, revenue cycle management and financial services, e-services, practice technology, and network and hardware services, as well as consulting, and continuing education services. Henry Schein, Inc. was founded in 1932 and is headquartered in Melville, New York.
Net sales increased by 0.4% from $3,162 million in Q3 2023 to $3,174 million in Q3 2024. This indicates a marginal growth in the company's revenue generation compared to the same period last year.
Net income decreased from $143 million in Q3 2023 to $99 million in Q3 2024, representing a 30.8% decline. This suggests potential challenges in profitability or increased expenses.
Operating income decreased from $200 million in Q3 2023 to $157 million in Q3 2024, a 21.5% decrease. This indicates a decline in the company's core operational profitability.